Can I read Islet Amyloid Polypeptide Amide Causes Peripheral Insulin Resistance in Vivo in Dogs on EtoBox?

Islet Amyloid Polypeptide Amide Causes Peripheral Insulin Resistance in Vivo in Dogs by R. Sowa; T. Sanke; J. Hirayama; H. Tabata; H. Furuta; S. Nishimura; K. Nanjo is a Medicine article available to read on EtoBox.

What is Islet Amyloid Polypeptide Amide Causes Peripheral Insulin Resistance in Vivo in Dogs about?

Islet amyloid polypeptide is a 37 amino acid hormone-like peptide which is the major protein component of islet amyloid deposits commonly found in patients with Type 2 (non-insulin-dependent) diabetes mellitus. Recent studies indicate that a physiologically active form of this peptide appears to be carboxyamidated and secreted from the insulin-producing beta cell. In order to clarify the possible in vivo actions of islet arnyloid polypeptide, we have studied the effects of synthesized islet amyloid polypeptide-amide on peripheral glucose utilization by performing hyperinsulinaemic euglycaemic glucose clamp studies on dogs. Exogenously administered islet amyloid polypeptide-amide (an infusion from 1.0 to 100 gg. kg ~. h -1, over 2 h) inhibited the insulinstimulated glucose disposal rate in a dose dependent manner. Twenty-five btg. kg-z-h-~ of islet amyloid polypeptide-amide infused via a peripheral vein significantly lowered the glucose disposal rate by 20% (from 17.4 + 1.7 to 14.4 + 1.7 mg. kg 1. min-~, n = 5, p < 0.01). These findings suggest that islet amyloid polypeptide-amide causes peripheral insulin resistance in vivo.

Who reads Islet Amyloid Polypeptide Amide Causes Peripheral Insulin Resistance in Vivo in Dogs?

Author

R. Sowa; T. Sanke; J. Hirayama; H. Tabata; H. Furuta; S. Nishimura; K. Nanjo

Publisher

Springer; Springer-Verlag; Springer Verlag; Springer Science and Business Media LLC (ISSN 0012-186X)

Published

1990

Language

EN

Field

Medicine (Health Sciences)